Sri Lanka has a small pharmaceutical market relative to many others within the Asia Pacific region. Although substantially smaller than peers India and Bangladesh, the country commands a larger drug market than Myanmar or Cambodia. In 2017, Sri Lanka's drug market reached LKR97.9bn (USD642mn). On a per capita basis, pharmaceutical spending amounted to USD30, with generic drugs remaining a dominant part of the sector. Healthcare expenditure in Sri Lanka amounted to LKR417.3bn (USD2.7bn) in 2017. Improving access to healthcare remains a key government priority, with public health spending accounting for 55% of total health spending and expected to continue increasing. While private healthcare spending will also continue to increase, public health expenditure will continue to dominate, increasing from LKR228.2bn (USD1.5bn) in 2017 to LKR449.6bn (USD2.7bn) in 2022.

Key View

SWOT

Industry Forecast

Pharmaceutical Market Forecast

Healthcare Market Forecast

Prescription Drug Market Forecast

Pharmaceutical Trade Forecast

Industry Risk/Reward Index

Asia Pacific Innovative Pharmaceuticals & Healthcare Risk/Reward Index

Sri Lanka Innovative Pharmaceuticals Risk/Reward Index

Regulatory Development

Regulatory Review

Market Overview

Competitive Landscape

Company Profile

GlaxoSmithKline

Hemas Holdings

State Pharmaceuticals Corporation (SPC)

Sri Lanka Demographic Outlook

Pharmaceuticals & Healthcare Glossary

Pharmaceuticals & Healthcare Methodology